← All trials
NCT04814472
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 16, 2021
- Primary completion
- Aug 17, 2021
- Completion date
- Nov 3, 2021
- First posted
- Mar 24, 2021
- Last posted
- Nov 10, 2021
- Enrollment
- 34
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Blade TherapeuticsLead sponsor
- Scientia Clinical Research Limited SydneyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.